Edit
Progentix Orthobiology
http://www.progentix.com/Last activity: 03.08.2021
Active - Reference to NuVasive
Progentix Orthobiology is developing synthetic bone substitutes designed to accelerate bone healing through a novel micro-structure. Nuvasive acquired Progrentix in 2009.
Investors 1
| Date | Name | Website |
| 03.08.2021 | BioGenerat... | biogenerat... |
Mentions in press and media 13
| Date | Title | Description |
| 27.03.2021 | China’s Chime Biologics nets $190m funding led by VMS Group | Chime Biologics (Wuhan) Co., Ltd, contract development and manufacturing organisation, has completed over $190 million in its Series A+ round of financing led by Hong Kong’s alternative asset management player VMS Group. Fidelity Internatio... |
| 07.01.2021 | Biocon Biologics gets capital injection of $150 mn from Goldman Sachs | Biopharmaceutical major Biocon has announced that the Board of its subsidiary Biocon Biologics has approved a capital injection of $150 million from global banking and investment firm Goldman Sachs. According to the terms of the proposed ag... |
| 07.01.2021 | India: Biocon Biologics raises $75.6m from Abu Dhabi’s ADQ, gets valued at $4b | Biotechnology major Biocon on Thursday said its subsidiary Biocon Biologics got capital injection of ₹555 crore from Abu Dhabi-based ADQ. The transaction values the Biocon unit at $4.17 billion. Post the completion of this transaction, Bioc... |
| 07.01.2021 | [Funding alert] Biocon Biologics raises Rs 555Cr from Abu Dhabi-based ADR at $4.17B valuation | Biocon Biologics Ltd, a subsidiary of Indian biopharmaceutical major Biocon, on Thursday said it has approved a primary equity investment from Abu Dhabi-based holding company ADQ. According to an official statement, ADQ will be investing Rs... |
| 10.11.2020 | India: Goldman Sachs to invest $150m in Biocon Biologics | Biocon Biologics, a subsidiary of biotechnology major Biocon Ltd, has secured its board’s approval for an investment of $150 million (Rs 1,125 crore) from US-based investment bank Goldman Sachs. As part of the agreement, Goldman Sachs will ... |
| 09.11.2020 | Biocon Biologics gets third PE cheque this year as Goldman bets $150 mn | Biopharmaceuticals company Biocon Ltd’s biosimilars unit is getting a big funding cheque from Goldman Sachs, after roping in private equity firms True North and Tata Capital Growth Fund earlier this year. Biocon said in a stock market discl... |
| 31.07.2020 | Tata Capital Growth Fund to invest ₹225 cr in Biocon Biologics | Biocon Ltd, a global biopharmaceuticals company, announced on Friday that the board of its subsidiary Biocon Biologics India Limited has approved a primary equity investment by Tata Capital Growth Fund. As per the terms of the proposed agre... |
| 05.01.2016 | Vivex Biologics gets $6.6M for next-gen implant tech | It offers a number of products – such as AlloGen, an amniotic fluid therapy that’s full of growth factors and cytokines that help with wound healing, cell proliferation and tissue protection. Rather than viewing implants as simple support s... |
| 30.12.2015 | Solstice Biologics raises $4M – but where did CEO Lou Tartaglia go? | But Lou Tartaglia, a former partner at Boston-based Third Rock Ventures with a long history in successful startup launch, joined Solstice in June 2014 – an indication that the broader investment community stood behind the company’s RNAi sci... |
| 20.08.2014 | Batu Biologics Completes $100,000 Crowdfunding | Samuel Wagner -- photo courtesy of Batu Biologics A San Diego-based immunotherapy company has successfully completed $100,000 of financing by utilizing an unusual fundraising approach — crowdfunding. Batu Biologics Inc. launched the crowd f... |
Show more